Elanco Animal Health Incorporated $ELAN Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 34.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,355,772 shares of the company’s stock after acquiring an additional 2,126,727 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 1.67% of Elanco Animal Health worth $205,636,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Elanco Animal Health in the first quarter valued at about $2,065,000. Goldman Sachs Group Inc. lifted its stake in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares in the last quarter. Empowered Funds LLC boosted its holdings in Elanco Animal Health by 35.2% in the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after buying an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Elanco Animal Health by 4.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after buying an additional 76,408 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in Elanco Animal Health by 2,006.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock worth $4,432,000 after buying an additional 295,651 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Michael J. Harrington acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were purchased at an average cost of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the acquisition, the director owned 131,451 shares of the company’s stock, valued at approximately $2,868,260.82. The trade was a 3.95% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Robert M. Vanhimbergen acquired 4,200 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $23.08 per share, with a total value of $96,936.00. Following the completion of the transaction, the chief financial officer directly owned 137,516 shares of the company’s stock, valued at $3,173,869.28. This trade represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 63,198 shares of company stock worth $1,473,109. Insiders own 1.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. TD Cowen raised their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. KeyCorp upped their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Finally, Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Price Performance

ELAN stock opened at $22.89 on Friday. Elanco Animal Health Incorporated has a 1 year low of $18.22 and a 1 year high of $27.98. The firm has a market capitalization of $11.44 billion, a PE ratio of -55.83, a price-to-earnings-growth ratio of 1.76 and a beta of 1.68. The business has a 50 day simple moving average of $24.57 and a 200-day simple moving average of $23.93. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the previous year, the firm earned $0.26 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities research analysts anticipate that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites, improve animal well-being and support productivity in livestock and aquaculture.

The company’s products include vaccines, parasiticides, antibiotics, animal health pharmaceuticals and nutritional supplements. Its companion animal portfolio serves dogs and cats, while its livestock business provides products for cattle, poultry, swine and aquaculture operations.